Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 5/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 3/20 | 0.40 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.39 |
| ▸ | FAHD1 | Q6P587 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Glycolic Acid SCHEMBL14481648 | 0.96 | CA4 (0.47) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL331529 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL991430 | 0.91 | — | — | |
| Glycolic Acid SCHEMBL134226 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL4555780 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL15441504 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL4522823 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL26512 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL1002389 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 | |
| Glycolic Acid SCHEMBL21297631 | 0.91 | CA4 (0.50) | CA4OR51E2CASP1CA1FFAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2021-05-25 | — | — | US | disclosed |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | THIOREDOXIN SYSTEMS AB (SE) | 2018-08-28 | — | — | US | disclosed |
| US-8425880-B1 | Metal-containing materials for treatment of bacterial conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-23 | — | — | US | disclosed |
| US-20130095184-A1 | Metal-Containing Materials for Treatment of Bacterial Conditions | NUCRYST PHARMACEUTICALS CORP. (CA) | 2013-04-18 | — | — | US | disclosed |
| EP-2043611-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | Nucryst Pharmaceuticals Corp. (CA) | 2009-04-08 | — | — | EP | disclosed |
| WO-2009014781-A2 | METAL-CONTAINING MATERIALS FOR TREATMENT OF BACTERIAL CONDITIONS | NUCRYST PHARMACEUTICALS CORP. (CA) | 2009-01-29 | — | — | WO | disclosed |
| US-20080050452-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-28 | — | — | US | disclosed |
| US-20080044491-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-02-21 | — | — | US | disclosed |
| US-20080014247-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| US-20080014278-A1 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS | 2008-01-17 | — | — | US | disclosed |
| WO-2008005705-A2 | METAL-CONTAINING FORMULATIONS AND METHODS OF USE | NUCRYST PHARMACEUTICALS CORP. (CA) | 2008-01-10 | — | — | WO | disclosed |
| EP-1483050-A1 | CATALYSTS HAVING CONTROLLED (111) CRYSTAL FACE EXPOSURE | Zhou, Bing (US) | 2004-12-08 | — | — | EP | disclosed |
| US-6746597-B2 | SEQUESTERING NOBLE METAL CATION BEFORE DEPOSITION ON CATALYST SUPPORT | HYDROCARBON TECHNOLOGIES, INC. | 2004-06-08 | — | — | US | disclosed |
| US-20030232721-A1 | Supported noble metal nanometer catalyst particles containing controlled (111) crystal face exposure | HYDROCARBON TECHNOLOGIES INC. | 2003-12-18 | — | — | US | disclosed |
| WO-2003064037-A1 | CATALYSTS HAVING CONTROLLED (111) CRYSTAL FACE EXPOSURE | HYDROCARBON TECHNOLOGY, INC. (US) | 2003-08-07 | — | — | WO | disclosed |
| EP-0390138-B1 | Platinum complexes and antitumor agents containing them as an active ingredient | SHIONOGI & CO (JP) | 1994-01-05 | — | — | EP | disclosed |
| US-4968826-A | REDUCED TOXICITY | SHIONOGI & CO., LTD. (JP) | 1990-11-06 | — | — | US | disclosed |
| EP-0390138-A1 | Platinum complexes and antitumor agents containing them as an active ingredient | SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI & CO. LTD. (JP) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11013730-B1 | Composition comprising selenazol or thiazalone derivatives and silver and method of treatment therewith | SELENOI, TST, SCLY | CA4 4079/4885OR51E2 2821/4885CASP1 587/4885 |
| US-10058542-B1 | Composition comprising selenazol or thiazolone derivatives and silver and method of treatment therewith | SELENOI, TST, GSS | CA4 4062/4885OR51E2 1733/4885CASP1 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.